世界の抗けいれん薬市場の規模、シェア、トレンド分析レポート – 業界の概要と2031年までの予測

Get Exclusive Sample PDF of this Report Here

抗けいれん薬市場分析

抗てんかん薬の世界市場は、てんかんやその他の神経疾患の罹患率の増加に牽引され、大幅な成長を遂げています。薬剤処方の進歩、てんかんに対する意識の高まり、効果的な治療オプションの需要などの要因が、市場拡大に貢献しています。さらに、発作性疾患にかかりやすい高齢者人口の増加が、市場の可能性をさらに高めています。北米は、医療費の高騰と活発な研究活動により、大きなシェアを占めています。対照的に、アジア太平洋地域は、医療インフラの改善と患者数の増加により、主要なプレーヤーとして浮上しています。この市場は、多くの製薬会社がイノベーションと戦略的パートナーシップに注力して製品提供を強化しているという競争の激しい環境が特徴です。

抗けいれん薬市場規模

世界の抗けいれん薬市場規模は、2023年に70億8,000万米ドルと評価され、2024年から2031年の予測期間中に4.90%のCAGRで成長し、2031年までに103億9,000万米ドルに達すると予測されています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、Data Bridge Market Researchがまとめた市場レポートには、詳細な専門家分析、患者の疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

抗けいれん薬市場の動向

「個別化医療の発展の加速」

抗てんかん薬市場では、個々の患者のプロファイルに合わせて治療をカスタマイズする個別化医療の開発に向けた顕著な傾向が見られます。このアプローチは、さまざまな抗てんかん薬に対する患者の独自の反応に対処し、有効性を高め、副作用を最小限に抑えます。たとえば、遺伝子検査は、ラモトリギンやレベチラセタムなどのどの薬剤が特定の患者に最も効果的であるかを判断するのに役立ちます。この傾向により、医療提供者が精密医療の実践を採用するにつれて、患者の転帰が改善され、市場の成長が促進されます。その結果、製薬会社は標的療法の開発研究に投資し、てんかん治療の状況をさらに変革し、抗てんかん薬市場の将来を形成しています。

レポートの範囲と抗けいれん薬市場のセグメンテーション     

Get Exclusive Sample PDF of this Report Here

抗けいれん薬市場の定義

抗けいれん薬は、てんかんやその他の発作性疾患を持つ人の発作を予防または頻度を減らすために主に使用される薬です。脳内の電気活動を安定させることで、発作の発生を最小限に抑えます。これらの薬は、双極性障害や神経障害性疼痛などの他の症状にも処方されます。一般的な例としては、カルバマゼピン、フェニトイン、バルプロ酸などがあります。効果と副作用は患者によって大きく異なるため、医療従事者による慎重な選択と監視が必要です。

抗けいれん薬市場の動向

ドライバー

• てんかんの罹患率の増加

てんかんの罹患率の増加は抗けいれん薬の需要を大幅に押し上げており、世界保健機関は世界中で約 5,000 万人がこの神経疾患に罹患していると推定しています。近年、てんかんの発症率は 1,000 人あたり約 5 ～ 10 件と報告されており、効果的な治療オプションの必要性が高まっています。さらに、診断技術の進歩と発作性疾患に対する認識の高まりにより、罹患した個人をより正確に特定できるようになり、より多くの患者がタイムリーな治療を受けられるようになりました。この認識の高まりとそれに伴う効果的な抗けいれん薬の需要は、医療提供者がこの慢性疾患を効果的に管理しようと努める中で、大きな市場牽引力となっています。

• 神経疾患の増加

The increase in neurological disorders significantly contributes to the growing demand for anticonvulsants, as conditions such Alzheimer’s disease and traumatic brain injuries often lead to seizures. According to the Alzheimer's Association, over 6 million Americans aged 65 and older are living with Alzheimer's disease, a number expected to rise as the population ages. Additionally, the Centers for Disease Control and Prevention (CDC) reports that traumatic brain injuries affect over 2 million people annually in the U.S., with a substantial proportion experiencing seizures as a consequence. These statistics illustrate the correlation between rising neurological disorders and the need for effective anticonvulsant therapies. As healthcare providers aim to manage the complexities associated with these conditions, the demand for anticonvulsants is expected to increase, positioning this factor as a critical market driver.

Opportunities

• Increasing Advancements in Drug Development

Advancements in drug development have significantly influenced the anticonvulsant market by introducing newer medications with enhanced efficacy and safety profiles, presenting substantial market opportunities. For instance, medications such as Lacosamide and Perampanel have emerged in recent years, providing alternatives for patients who do not respond well to traditional treatments. Lacosamide, approved in the U.S. in 2008, has shown effectiveness in treating partial-onset seizures and has a favorable safety profile, making it a preferred choice for many patients. Furthermore, innovations in drug formulation and delivery methods, such as extended-release formulations and personalized medicine approaches, allow for better patient adherence and optimized therapeutic outcomes. These continuous developments highlight the potential for growth in the anticonvulsant market as pharmaceutical companies invest in research and innovation to meet the evolving needs of patients.

• Growing Awareness and Improved Diagnosis

Growing awareness and improved diagnosis of neurological disorders have significantly expanded the patient population in need of anticonvulsant therapies, creating a valuable market opportunity. Initiatives such as public awareness campaigns and educational programs for healthcare providers have led to increased recognition of symptoms associated with epilepsy and other seizure disorders. For instance, the Epilepsy Foundation's "Seize the Awareness" campaign aims to educate both the public and medical professionals about seizure recognition and response, contributing to more timely diagnoses. This heightened awareness facilitates early intervention and drives demand for effective anticonvulsant treatments, providing pharmaceutical companies with the opportunity to cater to a growing market of newly diagnosed patients.

Restraints/Challenges

• Adverse Effects and Side Effects

Adverse effects and side effects associated with anticonvulsant medications pose significant challenges to patient compliance, often leading to non-adherence to treatment regimens. Common side effects include dizziness, fatigue, and cognitive impairment, which can deter patients from continuing their prescribed therapies. For instance, medications such as Carbamazepine and Lamotrigine are effective in managing seizures but can cause drowsiness and cognitive dulling, leading patients to skip doses or abandon treatment altogether. Furthermore, long-term safety concerns related to these medications, such as potential organ damage or increased risk of suicidal thoughts, can create apprehension among both patients and healthcare providers. This hesitance to utilize certain anticonvulsants due to fear of long-term consequences affects individual patient outcomes and presents a broader market challenge, as it limits the adoption of potentially effective therapies in clinical practice.

• High Treatment Costs Associated Novel Therapies

High treatment costs associated with certain anticonvulsants, particularly novel therapies, present a significant barrier to access for patients, especially in low- and middle-income countries. For instance, newer medications such as Brivaracetam and Lacosamide can be significantly more expensive than traditional anticonvulsants, making them unaffordable for many patients who rely on these treatments for seizure management. Additionally, inconsistent reimbursement policies across various regions exacerbate this issue, as some countries may not cover the costs of these newer medications under their national health insurance programs, limiting access for those who need them most. In regions where reimbursement is lacking or varies widely, patients may be forced to choose less effective, older therapies due to financial constraints, which impacts individual health outcomes and stifles overall market growth.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Anticonvulsants Market Scope

The market is segmented on the basis of drug class, dosage, route of administration, application, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Pyrimidinediones
• Benzodiazepines
• Fructose derivatives
• Aromatic allylic alcohols
• Valproylamides
• Carboxamides
• Bromides
• Carbamates
• Aldehydes
• Sulfonamides
• Pyrrolidines
• Triazines
• Fatty acids
• Propionates
• Oxazolidinediones
• Hydantoins
• Barbiturates
• Others

Dosage

• Tablet
• Capsule
• Liquid
• Rectal Gel
• Cream
• Others

Route of Administration

• Topical
• Enteral
• Parenteral

Application

• Migraine
• Epilepsy
• Neuropathic pain
• Anxiety
• Fibromyalgia
• Bipolar Disorder
• Borderline Personality Disorder

End Users

• Clinic
• Hospital
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Anticonvulsants Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, drug class, dosage, route of administration, application, end user, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is anticipated to lead the global Anticonvulsants market, primarily driven by significant investments in the healthcare sector that are projected to stimulate market expansion. Within this region, the United States is expected to take the lead, largely due to its rapid technological advancements in healthcare solutions and innovative treatment options. Additionally, the growing emphasis on early disease detection and personalized medicine in the U.S. further enhances the demand for Anticonvulsants, contributing to the region's dominance in this market.

The Asia-Pacific region is projected to experience significant growth from 2024 to 2031, largely fueled by the availability of azithromycin in both generic and branded forms, making it more accessible to patients. The rapid advancements in the biopharmaceutical sector contribute to the development of innovative therapies, further driving market expansion. Increased research and development activities in the region are fostering a dynamic environment for drug discovery and improvement. Additionally, ongoing developments in the healthcare sector, along with strong government support and initiatives aimed at enhancing healthcare access and affordability, are set to bolster the overall growth of the anticonvulsants market in Asia-Pacific.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Anticonvulsants Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Anticonvulsants Market Leaders Operating in the Market Are:

• Novartis AG (Switzerland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• Johnson & Johnson Private Limited (U.S.)
• Abbott (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Bausch Health Companies Inc. (U.S.)
• UCB S.A. (Belgium)
• Sunovion Pharmaceuticals Inc. (U.S.)
• GW Pharmaceuticals plc (U.K.)
• AstraZeneca (U.K.)
• GSK plc (U.K.)
• H. Lundbeck A/S (Denmark)
• Takeda Pharmaceutical Company Limited (Japan)
• Sumitomo Dainippon Pharma Co., Ltd (Japan)
• Biocon (India)
• Merck KGaA (Germany)
• Cadila (India)
• Eisai Co., Ltd (Japan)
• Cipla (India)
• Glenmark Pharmaceuticals Limited (India)
• Mankind Pharma (India)
• Novo Nordisk A/S (Denmark)
• Otsuka America Pharmaceutical, Inc (Japan)
• Wockhardt (India)

Latest Developments in Anticonvulsants Market

• In December 2022, Eisai Co., Ltd. announced an agreement to transfer the U.S. commercial rights for the antiepileptic drug (AED) Fycompa to Catalyst Pharmaceuticals, Inc., granting Catalyst an exclusive negotiation period for a potential asset within Eisai’s epilepsy pipeline
• 2022年8月、UCB SAはボヌール小児病院、ウィスコンシン健康情報機構（WHIO）、イェール大学と3つの包括的契約を締結しました。これらのパートナーシップは、発作群発患者が直面する課題をさらに深く掘り下げ、この病気の認知度を高めることを目的としています。
• 2022年2月、バイオヘイブン・ファーマシューティカル・ホールディング・カンパニーは、てんかん、疼痛障害、情動障害などの適応症を対象としたKv7チャネル活性化剤をチャネル・バイオサイエンスLLCから買収する契約を締結した。
• 2021年8月、UCB SAは、米国食品医薬品局（FDA）から、錠剤、注射剤、経口液剤の形でBRIVIACT（ブリバラセタム）の適応拡大の承認を取得し、生後1か月の幼児の部分発作患者の治療を可能にしました。
• 2021年8月、ファイザー社とフリン・ファーマ社は、英国競争・市場庁（CMA）から、一般的に使用されているてんかん治療薬の費用を国民保健サービス（NHS）に過剰請求したとして8,400万ドルの罰金を科せられた。

SKU-66107